KBO Systems Aims to Map the Brain Under Anesthesia

In the operating room, the brain's state is a black box. Anesthesiologists manage a delicate balance of consciousness, pain relief, and paralysis, guided by vital signs and clinical experience, but with limited direct insight into the organ most vulnerable to the cocktail of drugs. For older adults and high-risk patients, the stakes are especially high, with postoperative cognitive dysfunction a known, yet poorly predicted, complication. KBO Systems, founded in 2023, is betting that a stream of non-invasive brainwave data, processed by machine learning, can illuminate that darkness in real time [Tracxn, Unknown] [Perplexity Sonar Pro Brief, Unknown].

The EEG Wedge in the OR

The company's core bet is on the clinical utility of processed electroencephalogram (EEG) and auditory evoked potential (AEP) signals. While raw EEG has been available for decades, its interpretation during surgery has been complex and subjective. KBO's platform, which it calls the Perioperative Brain Health Platform, uses statistical signal processing and machine learning to translate those electrophysiological signals into a simplified readout of brain state [Perplexity Sonar Pro Brief, Unknown]. The goal is to provide anesthesiologists with a real-time, personalized guide for sedation management, potentially reducing drug overdoses and predicting a patient's risk of delayed cognitive recovery after surgery [Prospeo, Unknown]. The company is also developing a specific system, PASS (Paralytic and Sedation System), focused on monitoring patients receiving neuromuscular blocking agents [Tracxn, Unknown].

A Market Measured in Complications

The financial impetus for such a tool is substantial. According to one analysis, the problem of monitoring sedation and paralytic medications represents a $155 billion annual challenge [Thunderview CEO Dinners, 2026]. That figure speaks to the immense costs of complications, extended hospital stays, and long-term care associated with adverse neurological outcomes from surgery. KBO's focus on older adults and higher-risk patients targets a population where these complications are both more common and more costly, aiming to position its platform as a tool for improving both patient outcomes and hospital economics [Perplexity Sonar Pro Brief, Unknown]. The company is associated with the Medical Technology Enterprise Consortium (MTEC), suggesting an early focus on navigating the complex regulatory and validation pathways required for medical devices [Perplexity Sonar Pro Brief, Unknown].

The Founders and the Path Ahead

KBO Systems is led by co-founders Kevin Goehl, who serves as CEO, and Rocky Cagle [Tracxn, Unknown]. Public details on their backgrounds are limited, but Goehl is also listed as a co-founder at Greenflare, another venture [LinkedIn, Unknown]. The company appears to be in a very early, pre-seed stage of development, with no institutional funding rounds or named customer deployments yet disclosed in the public record. This places KBO squarely in the realm of prototype development and early clinical validation, a critical phase for any medical device startup.

The road from concept to cleared medical device is long and paved with regulatory milestones. The company's most immediate challenges are not commercial, but scientific and clinical.

• Algorithm validation. The core AI models must be trained and validated on diverse, high-quality datasets to prove they can reliably and safely interpret brain signals across a wide range of patients and surgical procedures.
• Regulatory strategy. Achieving FDA clearance, likely through the 510(k) or De Novo pathways, will require rigorous clinical studies demonstrating substantial equivalence or safety and effectiveness.
• Clinical integration. Even with a cleared device, adoption requires proving the platform fits seamlessly into high-pressure OR workflows and provides actionable insights that meaningfully change clinician behavior for the better.

Success for KBO Systems would mean giving anesthesiologists a new, objective lens on the brain. The condition in focus is perioperative neurocognitive disorders, a spectrum of cognitive impairments affecting memory, attention, and executive function that can emerge after surgery. The patient population is primarily older surgical patients, who are disproportionately affected. Today, the standard of care involves preoperative screening for risk factors and postoperative monitoring for symptoms, but intraoperative monitoring of brain state is not routine. Anesthesia depth is typically inferred from hemodynamic stability and drug pharmacokinetics, not from direct neural readouts. KBO's ambition is to move brain health from a postoperative concern to a continuously managed vital sign, transforming a reactive process into a guided, preventative one.

Sources

1. [Tracxn, Unknown] KBO Systems Company Profile | https://tracxn.com/d/companies/kbosystems/__nU-ogZ0iB6QnrLxFDSdW1MC-NXlSI27n9JJhgWiDnpU
2. [Perplexity Sonar Pro Brief, Unknown] KBO Systems Web-Grounded Brief
3. [Prospeo, Unknown] KBO Systems Overview | https://prospeo.io/c/kbo-systems
4. [Thunderview CEO Dinners, 2026] CEO Dinners Mention
5. [LinkedIn, Unknown] Kevin Goehl Profile
6. [Sesamers, Unknown] KBO Systems Profile | https://sesamers.com/startups/kbo-systems